 |
Ultra Ostivone
by Douglas Labs
60 Capsules
Nutritional Support For Bone Health*
| Our Price: $44.30 | 
|
Ultra-Ostivone from Douglas Laboratories is a dietary supplement with highly absorbable calcium, vitamin D, and ipriflavone that provide outstanding nutritional support for bone structure and function.*
FUNCTIONS
The adult human body contains approximately 1,200 g of calcium, about 99% of which is present in the skeleton. Bone is constantly turning over, a continuous process of formation and resorption. In children and adolescents, the rate of formation of bone mineral predominates over the rate of resorption. Once one reaches peak bone mass, sometime between the age of 20 and 30, bone formation slows down and bone resorption begins to prevail over bone formation, beginning the cycle of progressive, age-associated bone demineralization. Therefore, in normal aging, there is a gradual loss of bone.*
The condition of reduced bone mineral density can increase risk of fractures and affects a large proportion of the elderly in developed countries. Caucasian and Asian women typically have low peak bone densities, and therefore, are at the greatest risk of fractures in later life. It is generally accepted that obtaining enough dietary calcium throughout life can significantly decrease the risk of fractures due to reduced bone density. Among other factors, such as regular exercise, gender and race, calcium supplementation during childhood and adolescence
appears to be a prerequisite for maintaining adequate bone density later in life. But even the elderly can benefit significantly from supplementation with dietary calcium.*
In women, bone loss is generally accelerated following menopause. The decline in estrogen levels associated with menopause appears to put women at increased risk for declining bone density and associated fractures. Ipriflavone, derived from naturally occurring isoflavones, promotes bone density by inhibiting bone resorption. Numerous studies of postmenopausal women and individuals whose bones are showing signs of demineralization have investigated the benefits of ipriflavone on bone health. Laboratory and clinical studies have
documented ipriflavone’s positive effects on bone density.*
Experts agree that ipriflavone appears to directly inhibit osteoclast activity, thereby decreasing bone resorption. Osteoclasts and osteoblasts are two primary types of bone cells. Osteoblasts, the more exterior cells, are responsible for bone mineralization. Osteoclasts, found beneath the osteoblasts, are responsible for bone resorption. When calcium levels in the blood drop, the osteoblasts change shape, allowing the osteoclaststo become exposed and release calcium from the bones to the rest of the body.*
Scientists suspect ipriflavone may also stimulate osteoblast activity. Since osteoblasts are responsible for laying down new bone, an increase in osteoblast activity would result in increased bone mineralization. This suggests that ipriflavone may not only inhibit the breakdown of existing bone, but also encourage the formation of new bone.*
Ipriflavone, together with adequate calcium and vitamin D, a key regulatory hormone for calcium and bone metabolism, offers non-estrogenic protection against excessive bone resorption. Unlike other well-known isoflavones, such as genistein found in soy foods, ipriflavone does not have estrogenic activity. Ipriflavone can be safely used in conjunction with natural phytoestrogens or with hormone replacement therapy.
Furthermore, ipriflavone provides a positive effect on bone health in women for whom hormone therapies are contraindicated.*
|
|
NOTE: Special Order Product Product - Special Shipping Required
This is a Special Order Product. We stock this in low quantities, due to low-to-moderate sales volume. If the product is on hand, we will ship immediately. If we are out of stock at the time of your order, we will order directly from the manufacturer, on your behalf. This could add an additional 2 to 5 business days to your delivery time. |
Supplement FactsServing Size: One (1) Capsule
Servings Per Container: 60 | | | | Amount
Per Serving | Daily
Value | | Vitamin D | 50 IU | 13% | Calcium
(From Calcium Citrate/Carbonate Complex) | 150 mg | 15% | | Ipriflavone
(Ostivone***) | 300 mg | ** | | | ***Ostivone is a trademark of TSI. |
** Daily Value Not Established. Percent Daily Values are based on a 2,000 calorie diet. |
|
 |
|
|
| Cellulose, Silica, Stearates (Vegetable Source) |
| |
| As a dietary supplement, one (1) capsule two (2) times daily, or more as directed by physician. |
| |
| Keep out of reach of children. ... Store in a cool, dry place. ... Do not use if outer seal is missing. |
| |
| This product contains NO yeast, wheat gluten, soy protein, milk/dairy, corn, sodium, sugar, starch, artificial coloring/flavoring, or preservatives. |
|
|
|
| Bone and Tooth Health, Brittle Bones, Osteoarthritis Nutrition |
| |
| Bones, Teeth - Tooth |
| |
Adami S, Bufalino L, Cervetti R, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Serni U, Vecchiet L, Passeri M. Ipriflavone prevents radial bone loss in postmenopausal women with low bone mass over 2 years. Osteoporos Int 1997;7:119-25.
Agnusdei D, Adami S, Cervetti R, Crepaldi G, Di Munno O, Fantasia L, Isaia GC, Letizia G, Ortolani S, Passeri M, et al. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 1992;19 Suppl 1:S43-8.
Bendich A, Leader S, Muhuri P. Supplemental calcium for the prevention of hip fracture: potential health-economic benefits. Clin Ther 1999;21:1058-72.
Benvenuti S, Petilli M, Frediani U, Tanini A, Fiorelli G, Bianchi S, Bernabei PA, Albanese C, Brandi ML. Binding and bioeffects of Ipriflavone on a human preosteoclastic cell line. Biochem Biophys Res Commun 1994;201:1084-9.
Bronner F. Calcium and osteoporosis. Am J Clin Nutr 1994;60:831-6.
Bronner F, Pansu D. Nutritional aspects of calcium absorption. J Nutr 1999;129:9-12.
Castelo-Branco C. Management of osteoporosis. An overview. Drugs Aging 1998;12:25-32.
Cheng SL, Zhang SF, Nelson TL, Warlow PM, Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its
metabolites. Calcif Tissue Int 1994;55:356-62.
Civitelli R. In vitro and in vivo effects of ipriflavone on bone formation and bone biomechanics. Calcif Tissue Int 1997;61:S12-4.
Civitelli R, Abbasi-Jarhomi SH, Halstead LR, Dimarogonas A. Ipriflavone improves bone density and biomechanical properties of adult male rat bones. Calcif Tissue Int 1995;56:215-9.
de Aloysio D, Gambacciani M, Altieri P, Ciaponi M, Ventura V, Mura M, Genazzani AR, Bottiglioni F. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol 1997;11:289-93.
Gambacciani M, Cappagli B, Piaggesi L, Ciaponi M, Genazzani AR. Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-agonists. Calcif Tissue Int 1997;61:S15-8.
Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, Genazzani AR. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 1997;28:75-81.
Gennari C, Adami S, Agnusdei D, Bufalino L, Cervetti R, Crepaldi G, Di Marco C, Di Munno O, Fantasia L, Isaia GC, Mazzuoli GF, Ortolani S, Passeri M, Serni U, Vecchiet L. Effect of chronic treatment with ipriflavone in postmenopausal women with low bone mass. Calcif Tissue Int 1997;61:S19-22.
Gennari C, Agnusdei D, Crepaldi G, Isaia G, Mazzuoli G, Ortolani S, Bufalino L, Passeri M. Effect of ipriflavone--a synthetic derivative of natural isoflavones-- on bone mass loss in the early years after menopause. Menopause 1998;5:9-15.
Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Diagnosis and management of
osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin
Ther 1999;21:1025-44.
Nardo F, Scrofani V, Costa G, Bellanca S, Petrovec MM, Clemenza F, Licciardello S. [Therapeutic protocols compared in the treatment of
postmenopausal osteoporotic disease]. Minerva Ginecol 1994;46:305-15.
Nozaki M, Hashimoto K, Inoue Y, Ogata R, Okuma A, Nakano H. Treatment of bone loss in oophorectomized women with a combination
of ipriflavone and conjugated equine estrogen. Int J Gynaecol Obstet 1998;62:69-75.
O'Brien KO. Combined calcium and vitamin D supplementation reduces bone loss and fracture incidence in older men and women. Nutr
Rev 1998;56:148-50.
Ohta H, Komukai S, Makita K, Masuzawa T, Nozawa S. Effects of 1- year ipriflavone treatment on lumbar bone mineral density and bone
metabolic markers in postmenopausal women with low bone mass. Horm Res 1999;51:178-83.
Petilli M, Fiorelli G, Benvenuti S, Frediani U, Gori F, Brandi ML. Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int 1995;56:160-5.
Reid IR. The roles of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998;27:389-98. |
|
 |
Our Price: $44.30 |
|
|
|
|
